ADVERTISEMENT
Novel Allogeneic CAR-T Products Appear Safe in LBCL and FL
06/21/2020
Sattva Swarup Neelapu, MD, MD Anderson Cancer Center, Houston, Texas, discusses early results from the ALPHA study suggesting that ALLO-501, a genetically modified anti-CD19 CAR T-cell product, and ALLO-647, an anti-CD52 monoclonal antibody, are safe and may be effective in large B-cell lymphoma (LBCL) or follicular lymphoma (FL). These results were presented at the virtual 2020 ASCO Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement